Subscribe
StockStudio Aerials / Shutterstock.com
12 November 2024NewsAmericasLiz Hockley

Teva fights for re-listing of inhaler patents at US appeals court

Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva asks Fed Circ to reverse inhaler patents loss
1 August 2024   Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Teva asks Fed Circ to reverse inhaler patents loss
1 August 2024   Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

More on this story

Americas
Teva asks Fed Circ to reverse inhaler patents loss
1 August 2024   Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York